Tilt Biotherapeutics, a Helsinki, Finland-based clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, raised USD25M in Series B funding.
The round was led by European Innovation Council (EIC) Fund, Lifeline Ventures, Finnish Industry Investment (TESI), and Stephen Industries Inc Oy.
The company intends to use the funds to support a Phase 2 clinical trial of its lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase 1b trial in melanoma in combination with TILs and other Phase 1b trials.
Led by CEO and Founder Akseli Hemminki, TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can activate T cells and destroy cancer cells.
Its patented Tilt technology can be delivered intravenously, locoregionally, or intratumorally. It modifies the tumor microenvironment and has a broader systemic effect. By making cold tumors hot, it eliminates cancer’s ability to evade immune responses, thereby enhancing immune checkpoint inhibitors or T-cell therapies such as tumor infiltrating lymphocyte (TIL) and CAR T therapies.
The company has an office in Boston and it secured over secured over €72M to date.
FinSMEs
13/05/2025